GlobeStar Therapeutics Corporation (GSTC)

0.0009 +0.0001 (+12.50%) At close: 03:26PM EDT

GlobeStar Therapeutics Corporation

719 Jadewin Avenue
Richland, WA 99352
United States
206 451 1970
https://www.globestartherapeutics.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Mr. James C. Katzaroff	President, CEO, Secretary, Principal Executive Officer & Chairman of the Board	180k	N/A	1957
Mr. Robert R. Hale Chicoski CPA	CFO, Treasurer, Secretary, Principal Financial & Accounting Officer	84k	N/A	1943
Ms. Brooke Greenwald	Chief Marketing Officer	N/A	N/A	N/A
Mr. David Croom	Executive Vice President	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

GlobeStar Therapeutics Corporation, a clinical stage pharmaceutical company, focuses on developing a patented formulation of drugs for the treatment of multiple sclerosis and other neurodegenerative diseases. It offers Amethyst, a compound intended to treat neurodegeneration. The company was formerly known as AngioSoma, Inc. and changed its name to GlobeStar Therapeutics Corporation in July 2021. GlobeStar Therapeutics Corporation is based in Richland, Washington.

Corporate governance

GlobeStar Therapeutics Corporation’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.